Glenmark Pharmaceuticals is currently trading at Rs. 565.95, up by 1.40 points or 0.25% from its previous closing of Rs. 564.55 on the BSE.
The scrip opened at Rs. 564.60 and has touched a high and low of Rs. 568.00 and Rs. 558.50 respectively. So far 10127 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.35 on 02-May-2014 and a 52 week low of Rs. 489.10 on 27-Nov-2013.
Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 532.00 respectively. The current market cap of the company is Rs. 15320.43 crore.
The promoters holding in the company stood at 48.29% while Institutions and Non-Institutions held 41.20% and 10.52% respectively.
Glenmark Pharmaceuticals is planning to set up a new manufacturing facility in the US. The company is planning to set up this manufacturing facility at Monroe Corporate Center, North Carolina USA. The facility will be spread over 100,000 sq. feet (around 15 acre plot) and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topical.
The company expects to start manufacturing activity by the end of the current financial year. This facility is dedicated only for the US market and is Glenmark’s first manufacturing facility in North America adding to its list of 14 plants in 4 countries- India, Brazil, Argentina and Czech Republic.
Glenmark which operates in North America through its subsidiary Glenmark Generics Inc. has a fast growing generics business with a robust portfolio of over 90 products authorized for distribution in the U.S. in niche segments like Dermatology, Hormones, Controlled Substances, Oncology and Modified Release products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |